Last reviewed · How we verify
Norepinephrine Bitartrate In 5% Dextrose (NOREPINEPHRINE)
Norepinephrine constricts blood vessels and stimulates the heart.
At a glance
| Generic name | NOREPINEPHRINE |
|---|---|
| Also known as | noradrenaline |
| Sponsor | Pfizer |
| Drug class | Catecholamine |
| Target | alpha-adrenergic receptors, beta-adrenergic receptors |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
| First approval | 1950 |
Mechanism of action
Norepinephrine works by constricting peripheral blood vessels through alpha-adrenergic action, which increases blood pressure. It also stimulates the heart and dilates coronary arteries through beta-adrenergic action, enhancing cardiac output.
Approved indications
- Acute exacerbation of asthma
- Asthma
- Asthma management
- Bronchiectasis
- Bronchitis
- Low blood pressure
- Pulmonary emphysema
Common side effects
- Multiple organ dysfunction syndrome
- Cardiogenic shock
- Septic shock
- Cardiac arrest
- Appendicolith
- Hypotension
- Metabolic acidosis
- Acute kidney injury
- Ventricular fibrillation
- Fatigue
- Appendicitis
- Sepsis
Drug interactions
- Inhalational Anesthetics
- isocarboxazid
- methylthioninium chloride
- phenelzine
- procarbazine
- tranylcypromine
Key clinical trials
- Clinical Outcome and Cost-effectiveness of Reduced Noradrenaline by Using a Lower Blood Pressure Target in Patients With Cardiogenic Shock From Acute Myocardial Infarction (PHASE4)
- Clinical Laboratory Evaluation of Chronic Autonomic Failure
- Diagnosis of Pheochromocytoma (PHASE1)
- The Analgesic Efficacy and Safety of Venlafaxine for Prevention of Postherpetic Neuralgia in Patients With Acute Herpes Zoster (NA)
- Double Plasma Separation and Adsorption in Acute-on-Chronic Liver Failure (DPMAS-ACLF Trial) (NA)
- Comparing Two Different Norepinephrine Infusion Rates for Prophylaxis Against Spinal-induced Hypotension in Elderly (NA)
- Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol (PHASE3)
- Angiotensin II in Liver Transplantation (PHASE2,PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Norepinephrine Bitartrate In 5% Dextrose CI brief — competitive landscape report
- Norepinephrine Bitartrate In 5% Dextrose updates RSS · CI watch RSS
- Pfizer portfolio CI